0001533615 false 0001533615 2023-05-10 2023-05-10 0001533615 us-gaap:CommonStockMember 2023-05-10 2023-05-10 0001533615 us-gaap:SeriesAPreferredStockMember 2023-05-10 2023-05-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares





Washington, D.C. 20549









Date of Report (Date of earliest event reported): May 10, 2023 (May 10, 2023)


Global Medical REIT Inc.

(Exact name of registrant as specified in its charter)


Maryland 001-37815 46-4757266
(State or other jurisdiction
of incorporation)
File Number)
(IRS Employer
Identification No.)


7373 Wisconsin Avenue, Suite 800

Bethesda, MD


(Address of principal executive offices)

(Zip Code)


(202) 524-6851

(Registrant’s telephone number, including area code)


Not Applicable

(Former name or former address, if changed since last report)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class:   Trading Symbols:   Name of each exchange on which registered:
Common Stock, par value $0.001 per share   GMRE   NYSE
Series A Preferred Stock, par value $0.001 per share   GMRE PrA   NYSE


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨






Item 5.07 Submission of Matters to a Vote of Security Holders.


On May 10, 2023, Global Medical REIT Inc. (the “Company”) held its 2023 annual meeting of stockholders (the “2023 Annual Meeting”). At the 2023 Annual Meeting, the Company’s stockholders: (i) elected the seven nominated directors to the Company’s Board of Directors, each to serve until the Company’s 2024 annual meeting of stockholders and until her or his successor is duly elected and qualifies, (ii) approved, on an advisory basis, the compensation of the Company’s named executive officers, and (iii) ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The full results of the matters voted on at the 2023 Annual Meeting are set forth below:


Proposal 1 — Election of Directors:


Nominee for Director  For  Against  Abstain  Broker Non-Votes
Jeffrey M. Busch  33,499,263  1,976,607  88,818  14,458,379
Matthew Cypher  34,415,131  1,061,383  88,174  14,458,379
Ronald Marston  34,321,181  1,160,535  82,971  14,458,380
Henry E. Cole  35,067,940  403,187  93,562  14,458,378
Zhang Huiqi  35,069,774  396,332  98,583  14,458,378
Paula R. Crowley  35,123,526  347,118  94,047  14,458,376
Lori Wittman  34,398,440  1,073,516  92,733  14,458,378


Proposal 2 — Advisory Vote on Named Executive Officer Compensation:


For   Against   Abstain   Broker Non-Votes
33,561,467   1,309,381   693,840   14,458,379


Proposal 3 — Ratification of Appointment of Independent Registered Public Accounting Firm:


For   Against   Abstain   Broker Non-Votes
49,809,327   101,966   111,774   0







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Global Medical REIT Inc.
  By:  /s/ Jamie A. Barber
    Jamie A. Barber
    Secretary and General Counsel
Date:  May 10, 2023